BiotechTube
Home/Kailera Therapeutics/Doug Pagán
DP

Doug Pagán

Chief Financial Officer

Kailera Therapeutics

Therapeutic Areas

ObesityChronic Weight Management

Kailera Therapeutics Pipeline

DrugIndicationPhase
Ribupatide (KAI-9531) InjectableObesity / Chronic Weight ManagementPhase 3
Ribupatide OralObesity / Chronic Weight ManagementPhase 2
KAI-7535Obesity / Chronic Weight ManagementClinical
KAI-4729Obesity / Chronic Weight ManagementClinical

Leadership Team at Kailera Therapeutics

RR
Ron Renaud
President & Chief Executive Officer
View full Kailera Therapeutics profile